Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2503145 | 0.81 | GAA (0.47) | KDM4EALDH1A1MAPK1LMNASMN1; SMN2 | |
| SCHEMBL29233512 | 0.81 | KDM4E (0.38) | KDM4EALDH1A1MAPK1LMNASMN1; SMN2 | |
| SCHEMBL29291504 | 0.81 | DPP4 (0.35) | ALDH1A1MAPK1LMNA | |
| SCHEMBL21435138 | 0.80 | NOS2 (0.42) | HSD17B10GLA | |
| SCHEMBL2573409 | 0.80 | ALDH1A1 (0.35) | ALDH1A1MAPK1LMNASMN1; SMN2 | |
| SCHEMBL25363482 | 0.78 | ALDH1A1 (0.57) | KDM4EALDH1A1MAPK1LMNAGAA | |
| SCHEMBL2224391 | 0.78 | ALDH1A1 (0.57) | KDM4EALDH1A1MAPK1LMNAGAA | |
| SCHEMBL28774060 | 0.78 | ALDH1A1 (0.57) | KDM4EALDH1A1MAPK1LMNAGAA | |
| SCHEMBL16632557 | 0.78 | HSD11B1 (0.34) | ALDH1A1TSHR | |
| SCHEMBL1769221 | 0.78 | CYP2C19 (0.39) | KDM4EALDH1A1LMNAGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| CN-108778273-B | Bicyclic aryl monocyclic beta-lactam compounds and methods of use thereof for treating bacterial infections | 默沙东公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-113874016-A | Compound and use thereof | 福宏治疗公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20210387998-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-12-16 | — | — | US | disclosed |
| US-11161855-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200040002-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2020-02-06 | — | — | US | disclosed |
| US-10370387-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-10364239-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-07-30 | — | — | US | disclosed |
| US-20180319783-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2018-11-08 | — | — | US | disclosed |
| WO-2017068089-A2 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| CN-105793265-A | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | 南京明德新药研发股份有限公司 | 2016-07-20 | — | — | CN | disclosed |
| US-20160024109-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160015695-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-9181271-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2917221-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014071031-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140121198-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2384328-A1 | 6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM | Boehringer Ingelheim International GmbH (DE) | 2011-11-09 | — | — | EP | disclosed |
| WO-2010060952-A1 | 6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | KDM4E 819/4885ALDH1A1 4431/4885MAPK1 680/4885 |
| US-20200040002-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | KDM4E 819/4885ALDH1A1 4431/4885MAPK1 680/4885 |
| US-20160015695-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | KDM4E 819/4885ALDH1A1 4431/4885MAPK1 680/4885 |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | KDM4E 819/4885ALDH1A1 4431/4885MAPK1 680/4885 |
| US-11161855-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | KDM4E 819/4885ALDH1A1 4431/4885MAPK1 680/4885 |
| US-20140121198-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | KDM4E 819/4885ALDH1A1 4431/4885MAPK1 680/4885 |
| US-20160024109-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | KDM4E 819/4885ALDH1A1 4431/4885MAPK1 680/4885 |
| US-10370387-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | KDM4E 819/4885ALDH1A1 4431/4885MAPK1 680/4885 |
| US-10364239-B2 | Ferroportin inhibitors | HAMP, SLC40A1, HMOX1 | KDM4E 4608/4885ALDH1A1 1716/4885MAPK1 2849/4885 |
| US-20210387998-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | KDM4E 819/4885ALDH1A1 4431/4885MAPK1 680/4885 |
| US-20180319783-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, FTH1 | KDM4E 4672/4885ALDH1A1 1983/4885MAPK1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.